Abstract
Purpose
The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery.
Methods
The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
Results
The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981, P < 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807, P = 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290, P = 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438, P = 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs.
Conclusion
The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer.
Similar content being viewed by others
Abbreviations
- ASA:
-
American Society of Anesthesiologists physical status
- BMI:
-
Body mass index
- CA19-9:
-
Carbohydrate antigen
- C–D:
-
Clavien–Dindo
- CEA:
-
Carcinoembryonic antigen
- CRC:
-
Colorectal cancer
- CRP:
-
C-reactive protein
- EMT:
-
Epithelial–mesenchymal transition
- GAR:
-
Globulin-to-albumin ratio
- LMR:
-
Lymphocyte-to-monocyte ratio
- NLR:
-
Neutrophil-to-lymphocyte ratio
- OS:
-
Overall survival
- PIV:
-
Pan-immune-inflammation value
- ROC:
-
Receiver operating characteristic
- SII:
-
Systemic-immune-inflammation index
- TNM:
-
Tumor-node-metastasis
- WBC:
-
White blood cell
References
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64:104–17.
Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.
Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4:309–15.
Jankova L, Dent OF, Chan C, Chapuis P, Clarke SJ. Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer. 2013;13:442.
Hachiya H, Ishizuka M, Takagi K, Iwasaki Y, Shibuya N, Nishi Y, et al. Clinical significance of the globulin-to-albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Ann Gastroenterol Surg. 2018;2:434–41.
Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K, et al. Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer. Oncol Lett. 2017;13:1000–6.
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261–72.
Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123:403–9.
Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status—historical perspectives and modern developments. Anaesthesia. 2019;74:373–9.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
Shida D, Kanemitsu Y, Hamaguchi T, Shimada Y. Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Jpn J Clin Oncol. 2019;49:321–8.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, et al. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunol Res. 2016;4:592–9.
Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, et al. CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight. 2018;3: e97022.
Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16:601–20.
Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, et al. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study. BMC Cancer. 2017;17:404.
Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711.
Shen Y, Guan Y, Hummel JJ, Shyu CR, Mitchem JB. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. BMC Cancer. 2020;20:124.
Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44:293–304.
Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets. 2018;29:569–73.
Park JH, Ishizuka M, McSorley ST, Kubota K, Roxburgh CSD, Nagata H, et al. Staging the tumor and staging the host: a two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. Am J Surg. 2018;216:458–64.
Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125:4139–47.
Miyamoto Y, Hiyoshi Y, Sawayama H, Tokunaga R, Baba H. Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Ann Gastroenterol Surg. 2020;4:635–45.
Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54–63.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.
Acknowledgements
We wish to thank TS, MI, TA and KK for their advice on the experimental design. We wish to thank KS, NS, HH, YI and KT for the timely help they provided in collecting the large number of patients.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest in association with the present study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sato, S., Shimizu, T., Ishizuka, M. et al. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery. Surg Today 52, 1160–1169 (2022). https://doi.org/10.1007/s00595-021-02448-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-021-02448-6